Table 1.
Baseline sociodemographic, clinical and physical characteristics
| Characteristic | Intervention group (N=23) | Control group (N=11) |
|---|---|---|
| Age, years | ||
| mean (SD) | 48.0 (9.4) | 48.0 (11.9) |
| Female, N (%) | 13 (56%) | 6 (55%) |
| Education, N (%) | ||
| low | 2 (9%) | 0 (0%) |
| middle | 10 (43%) | 6 (55%) |
| high | 11 (48%) | 5 (45%) |
| WHO tumour grade, N (%) | ||
| grade II | 16 (70%) | 6 (55%) |
| grade III | 7 (30%) | 5 (45%) |
| Tumour histology, N (%) | ||
| astrocytoma | 8 (35%) | 5 (46%) |
| oligodendroglioma | 12 (52%) | 5 (46%) |
| oligoastrocytoma | 3 (13%) | 1 (8%) |
| Disease duration, years | ||
| mean (SD) | 7.6 (4.9) | 8.5 (8.6) |
| Left hemisphere, N (%) | 10 (43%) | 4 (36%) |
| Surgery, N (%) | ||
| no | 0 | 1 (9%) |
| biopsy | 4 (17%) | 1 (9%) |
| resection | 19 ( 83%) | 9 (82%) |
| Chemotherapy, N (%) | 9 (39%) | 4 (36%) |
| Radiotherapy, N (%) | 14 (61%) | 5 (45%) |
| Epilepsy | 17 (73.9%) | 8 (72.7%) |
| Anti-epileptic drugs | 14 (60.9%) | 6 (54.5%) |
| VO2 peak absolute, ml/min | ||
| mean (SD) | 2,252.0 (728.0) | 2,181.5 (741.0) |
| VO2 peak relative, ml/kg/min | ||
| mean (SD) | 26.5 (7.4) | 25.9 (4.8) |
| VO2 peak classification, N (%) [10] | ||
| recreational (VS sedentary) | 4 (17%) | 1 (9%) |
| Self-reported physical activity, MET*min/week | ||
| median (25th; 75th percentile) | 4399.5 (1468.0; 8640.0) | 4583.5 (1838.0; 13,457.0) |
| Body weight, kg | ||
| mean (SD) | 84.8(11.2) | 83.7 (22.2) |
| BMI, kg/m2 | ||
| mean (SD) | 27.3 (3.0) | 27.3 (5.5) |
| Letter digit substitution task[14], number correct | ||
| mean (SD) | 43.9 (11.5) | 43.4 (10.0) |
| SF-36 Physical Component Scale [43, 44], scale 0–100 | ||
| mean (SD) | 44.7 (8.2) | 47.0 (7.8) |